<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569257</url>
  </required_header>
  <id_info>
    <org_study_id>AEZS-108-040</org_study_id>
    <secondary_id>AGO-GYN 5</secondary_id>
    <secondary_id>EudraCT No. 2007-002663-26</secondary_id>
    <nct_id>NCT00569257</nct_id>
  </id_info>
  <brief_title>Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors</brief_title>
  <official_title>Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether AEZS-108 shows anti-tumor activity and is
      tolerated in patients with gynecological tumors (ovarian / endometrial cancer) that have been
      shown to express receptors for the luteinizing hormone releasing hormone (LHRH)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ovary and the endometrium are hormone dependent organs. Receptors for different sex
      hormones are found commonly in epithelial ovarian and endometrial cancers. LHRH and its
      receptors are expressed in about 80% of human ovarian and endometrial cancers. As binding
      sites are present on tumors in higher concentrations than on most normal tissues, these
      receptors represent a specific target for AEZS-108 in which doxorubicin is coupled to an LHRH
      analog.

      Patients whose tumor specimen have shown to be positive for LHRH receptor expression will be
      investigated for tumor response and tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response as per RECIST or (for Ovarian CA patients without evaluable target lesion following RECIST) GCIG criteria</measure>
    <time_frame>up to six 3-weekly treatment cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression (TTP); Overall survival</measure>
    <time_frame>up to observation of event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of AEZS-108 (possibly drug-related adverse events)</measure>
    <time_frame>4 weeks beyond last drug admnistration</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">85</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEZS-108</intervention_name>
    <description>intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles</description>
    <other_name>AN-152</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LHRH receptor positive tumor status: positive receptor status determined by
             immunohistochemistry from primary tumor

          -  Histologically confirmed epithelial ovarian cancer (Stratum A)

          -  Advanced (FIGO III or IV) or recurrent disease

          -  Progression during treatment with a platinum-based regimen or within 6 months after
             receiving a platinum-based regimen

          -  Previous treatment with a taxane-containing regimen

          -  At least one measurable target lesion (RECIST criteria) OR CA125 level higher than
             twice the upper limit of normal range (GCIG criteria)

          -  Histologically confirmed endometrial cancer (Stratum B)

          -  Advanced (FIGO III or IV) or recurrent disease not amenable to potentially curative
             treatment with local surgery and/or radiation therapy

          -  No previous anthracycline-based chemotherapy

          -  At least one measurable target lesion according to RECIST criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Günter Emons, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäts-Frauenklinik / Department of Obstetrics and Gynecology, University of Göttingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital &quot;Dr. Georgy Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>BG-5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Hospital Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>BG-4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncodispensary &quot;M.Markov&quot;</name>
      <address>
        <city>Varna</city>
        <zip>BG-9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe, Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik, Klinikum Bremen-Mitte GmbH</name>
      <address>
        <city>Bremen</city>
        <zip>D-28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde, Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91094</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik, Universitätsklinikum</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik, Klinikum der JWG Universität Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>D-60591</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Ernst-Moritz-Arndt-Universitaet, Klinik und Poliklinik fuer Gynaekologie und Geburtshilfe</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik, Georg-August-Universität Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik, St. Vincentius Kliniken AG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik, Klinikum Lüneburg</name>
      <address>
        <city>Lüneburg</city>
        <zip>D-21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Suedstadt der Hansestadt Rostock, Universitaetsfrauenklinik und Poliklinik</name>
      <address>
        <city>Rostock</city>
        <zip>D-18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik f. Gynäkologie u. Gyn. Onkologie, Dr. Horst Schmidt Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de</url>
    <description>AGO Studiengruppe Ovarialkarzinom</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LHRH receptor</keyword>
  <keyword>receptor positive tumors</keyword>
  <keyword>platinum resistant ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

